Piramal Pharma Q1 FY25 net loss narrows

EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24

Laurus Labs posts Q1 FY25 consolidated PAT at Rs. 12.51 Cr

Laurus Labs has reported total income of Rs. 1,197.42 crores during the period ended June 30, 2024

Gland Pharma receives USFDA’s tentative approval for Latanoprostene Bunod Ophthalmic Solution

The product is bioequivalent and therapeutically equivalent to the reference listed drug

Shilpa Biologicals receives registration approval for Adalimumab from Morocco, MoH

Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL)

Zydus receives USFDA’s final approval for Valsartan Tablets

The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ - II, India

Thyrocare Technologies posts Q1 FY25 consolidated profit at Rs. 24.17 Cr

Thyrocare Technologies has reported total income of Rs. 160.53 crores during the period ended June 30, 2024

Torrent Pharmaceuticals posts Q1 FY25 consolidated PAT at Rs. 457 Cr

Torrent Pharmaceuticals has reported total income of Rs. 2,883 crores during the period ended June 30, 2024

Alembic receives USFDA’s final approval for Fluphenazine Hydrochloride Tablets

Syngene reports drop in Q1 FY25 revenue to Rs. 790 Cr

Reported profit after tax declined 19% year-on-year to Rs 76 crores

USFDA successfully inspects Carbogen Amcis’s manufacturing sites in Neuland and Aarau

The inspections concluded with no Form 483 observations or significant critical findings